Kevin Walton

Kevin Walton is the Chief Executive Officer and Board Director of Baseimmune, a London-based biotech using AI and computational protein design to build next-generation vaccines and active immunotherapies. He joined in 2024 after a career in biotech corporate development and dealmaking at Moderna, StrideBio, Curis and G1 Therapeutics, and is steering the company beyond infectious-disease vaccines into chronic diseases, starting with a lead fibrosis program in idiopathic pulmonary fibrosis.